Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib

Details for Australian Patent Application No. 2009206566 (hide)

Owner Novartis AG

Inventors Wang, Yanfeng; Wehrle, Elisabeth

Agent Davies Collison Cave

Pub. Number AU-A-2009206566

PCT Pub. Number WO2009/094360

Priority 61/022,945 23.01.08 US

Filing date 21 January 2009

Wipo publication date 30 July 2009

International Classifications

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

5 August 2010 PCT application entered the National Phase

  PCT publication WO2009/094360 Priority application(s): WO2009/094360

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009206580-Quinolizidinone M1 receptor positive allosteric modulators

2009206560-Method for forming an integral porous region in cast implant